Lek Donates Defibrillator to Ljubljana Festival
On Friday, May 30, the Manager and Artistic Director of the Ljubljana Festival, Darko Brlek, held a press conference with Slovene and Austrian journalists in the Knight’s Hall at the Križanke complex in Ljubljana and gave a brief presentation of the highlights of the upcoming 2008 Ljubljana Festival. One of the main topics of the press conference was the defibrillator that Lek has donated to the Ljubljana Festival. The defibrillator will be available for use by all employees of the Ljubljana Festival and visitors to events at Križanke. For some time, Lek has recognized the need for publicly accessible automatic defibrillators, which can take the place of emergency medical assistance in cases of stoppage of the heart or breathing.
At the press conference today, the Ljubljana Festival once again presented the program for this year’s festival, which includes a concert by the Moscow Chamber orchestra, which is sponsored by Lek, a Sandoz company.
The presentation of the program was followed by the presentation of the defibrillator, which Member of the Lek Board of Management Darija Brečevič presented to Manager and Artistic Director of the Ljubljana Festival Darko Brlek. Mrs. Brečevič said: “Caring for health and a better quality of life is one of the cornerstones of Lek’s mission. Through the various activities and projects that we support, we try to encourage preventive behavior and increase awareness of the importance of a healthy lifestyle. However, preventive actions are often too late, therefore at those times it is important to be prepared and most importantly to be capable of providing assistance. Therefore this year we are giving a defibrillator to the Ljubljana Festival, which every year holds events that are attended by large numbers of people. So it is right to do everything we can to protect people’s safety and provide first aid in case of accidents. The defibrillator we are donating is easy to use. In spite of this, the associates of the Ljubljana Festival will be taking training courses to learn how to use it and will thus be able to assist people in need with greater self-confidence. Of course we hope that they will have to use it as little as possible.”
The operation of the defibrillator was also presented at the press conference. It is an invaluable piece of equipment which can save the life of anyone who suffers a sudden stoppage of respiratory or heart functions. People who experience such attacks suddenly collapse and lie prostrate. In Slovenia there are 5.5 such cases per day on average. 95% of these people die before arriving at the hospital. Action must be taken immediately! An automatic defibrillator is a device which prevents heart fibrillation by passing a strong electrical shock between the electrodes which are attached to the patient’s chest, thus stimulating the heart to begin beating normally again. Darija Brečevič and Darko Brlek spoke about the importance and use of the defibrillator.
Lek recognized the need for publically accessible defibrillators as early as 2005, when they contributed funds for the purchase of two defibrillators: one is located in the pedestrian underpass at Maximarket, and the other travels around Slovenia. Last year they also donated a defibrillator to Radio Slovenija, which is publically accessible and intended for public use.
Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. It operates as a global development center for products and technologies, as a global manufacturing center for active pharmaceutical ingredients and medicines, as a competence center for the development of vertically integrated products, as a Sandoz competence center in the field of development and manufacturing of biosimilars and as a supply center for the markets of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz global markets. Lek d.d. employs more than 3,000 people. For further information please consult http://www.lek.si
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 950 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and EonLabs (US) In 2007, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.2 billion.
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group’s continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout
the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For further information contact:
Katarina Klemenc Dinjaški
Lek Pharmaceuticals d.d.
Phone: + 386 1 580 22 43
Fax: + 386 1 580 24 32